BioSpace News Archive

Biotech Bay

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.

September 5, 2022
·
9 min read
Biotimize Announces the Opening of a Fundraising Round to Build the First Biological CDMO in Brazil

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, announced the opening of a $30 million Series A fundraising round.

September 5, 2022
·
2 min read
Lunit to Showcase 5 Abstracts at ESMO 2022

Lunit announced the presentation of five abstracts highlighting the effectiveness of its AI-biomarker platform - Lunit SCOPE - at the European Society of Medical Oncology Congress 2022, held in Paris from September 9 to 13.

September 5, 2022
·
2 min read
Drug Development

Dizal Announces Positive Phase I Clinical Trial Results for DZD1516 in Treating HER2 Breast Cancer at 2022 ESMO

Dizal reported the promising safety and pharmacokinetic data from the global Phase I study of DZD1516 in patients with HER2 positive metastatic breast cancer who relapsed from multiple prior treatments at the 2022 European Society for Medical Oncology Annual Meeting.

September 5, 2022
·
4 min read
Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO

Dizal announced positive topline results from the first pivotal study of sunvozertinib in platinum-pretreated NSCLC Patients with EGFR exon20ins mutations at the European Society for Medical Oncology Annual Meeting.

September 5, 2022
·
5 min read
Drug Development

Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.

September 5, 2022
·
6 min read